Overall, 525 (55%), 420 (44%), 944 (99%), 948 (100%), and no strains from Dhaka and 186 (54%), 165 (48%), 332 (97%), 343 (100%), and no strains from Matlab were resistant to tetracycline, erythromycin, trimethoprim-sulphamethoxazole, furazolidone, and ciprofloxacin respectively. Prior to October 2004, most strains were resistant to trimethoprim-sulphamethoxazole and furazolidone but were uniformly sensitive to tetracycline, erythromycin, and ciprofloxacin.
The first multidrug-resistant strains of V. cholerae (strains resistant to furazolidone, trimethoprimsulphamethoxazole, tetracycline, and erythromycin) were observed in Based on the multidrug-resistant phenotype, it appeared that there were two or more clones of V. cholerae O1 in circulation at different time points, and we are in the process of understanding the clonality by subjecting representative strains to molecular typing analysis. We determined antimicrobial susceptibility using both disc-diffusion technique and E-test method.
In the absence of a reference zone size for V. cholerae resistance to erythromycin and azithromycin, we used the zone size for other organisms to determine the susceptibility (zone of inhibition ≥23 mm for erythromycin and ≥18 mm for azithromycin) of the V. cholerae strains to these drugs. Seventeen of the 35 (49%) V. cholerae strains were resistant to both erythromycin and azithromycin, while the remaining 18 (51%) strains were susceptible to both erythromycin and azithromycin. The strains resistant to erythromycin exhibited minimum inhibition concentrations (MICs) of 8 to 32 µg/mL, while the MIC of those susceptible to the drug ranged from 0.25 to 1 µg/mL. The MIC of the strains resistant to azithromycin ranged from 0.75 to 3 µg/mL, while the MIC of those susceptible to the drug was from 0.047 to 0.125 µg/mL. These findings suggest that resistance to erythromycin could be a marker for resistance to azithromycin. Similarly, resistance to tetracycline is considered a proxy indicator for resistance to doxycycline (5). We have, for the first time, encountered this unique, multidrug-resistant pattern, including resistance to erythromycin, among V. cholerae O1 in Bangladesh.
LETTER-TO-THE-EDITOR
Throughout the period of this investigation, all isolates from Matlab and Dhaka were susceptible to ciprofloxacin. The MIC for ciprofloxacin was determined using E-test (AB-BIODISK, Sweden) with the zone size interpretive criteria for susceptibility corresponding to 0.06 µg/mL (5). We noted a consistent increase in the median MIC of V. cholerae O1 strains isolated at the Dhaka Hospital over the years: 0.003 µg/mL in 1994, 0.023 µg/mL in 2001, and 0.38 to 0.5 µg/mL in 2005 (6,7). In a recent study in adults infected with V. cholerae O1, we observed clinical success (resolution of diarrhoea by 48 hours of initiation of therapy) rate of 68% with 500-mg 12-hourly dose of ciprofloxacin for three days-a rate substantially lower than that observed with a single one-gramme dose of the drug in an earlier study (8) .
The findings are disturbing since a further increase in the MIC may render ciprofloxacin ineffective in the management of cholera caused by such multidrug-resistant strains of V. cholerae O1. Further studies are being conducted at ICDDR,B to determine the mechanism of resistance of these multidrug-resistant strains to ciprofloxacin.
In August 2006, we observed a re-emergence of the Inaba serotype and a sharp reduction in the isolation rate of the Ogawa serotype. In Bangladesh, such changes in serotypes and the appearance of short-lasting, multidrug-resistance, have also been noted in the past (9, 10, 11) . The proportion of V. cholerae strains resistant to tetracycline decreased substantially (from 75% in January 2006 to 10% in August 2006). Resistance to tetracycline persisted for nearly two years, a finding that we have not observed earlier (12,13).
The current situation clearly demonstrates the need to monitor MIC in areas where cholera is endemic to assess the clinical efficacy of ciprofloxacin in the treatment of cholera. There is also a need to identify effective alterative antimicrobials for the management of cholera caused by such strains. Through this communication, we would also like to alert our neighbouring countries and the region of circulation of this new multidrug-resistant strain of V. cholerae O1.
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